文献速递肿瘤 PET/CT甲状腺核医学神经核医学

肿瘤学中的个体化PET显像:一项伞状综述——汇总Meta分析以指导放射性药物的合理选择与适应证

Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-09-11

该伞状综述汇总Meta分析,评估[18F]FDG、68Ga-DOTA肽、[18F]DOPA、PSMA靶向配体及FAPI在脑以外实体瘤诊断与分期中的准确性。最终纳入64项Meta分析,证据支持[18F]FDG在分子影像中的主要地位,PSMA用于前列腺癌分期与再分期,生长抑素靶向肽或[18F]DOPA用于神经内分泌肿瘤,FAPI在胃癌评估中崭露头角。部分癌种未筛选到满意的Meta分析。

要点

  • [18F]FDG仍是分子影像的主要手段;PSMA示踪剂有助于前列腺癌分期与再分期。
  • 生长抑素靶向肽(如[68Ga]Ga-DOTA-TOC和-DOTA-TATE)或[18F]DOPA在神经内分泌肿瘤中有价值。
  • FAPI在胃癌评估中崭露头角;部分癌种未筛选到满意的Meta分析。

核心结论

  • 该伞状综述综合的高级别证据可作为临床医生和影像医生的指南针,帮助他们在日益复杂的PET检查领域中导航。

研究设计与样本

  • 在PubMed/MEDLINE和EMBASE数据库系统检索评估PET/CT和/或PET/MRI准确性的Meta分析,最终纳入64项Meta分析。

主要发现

  • [18F]FDG是分子影像的主要手段;PSMA示踪剂在前列腺癌分期和再分期中有用;生长抑素靶向肽或[18F]DOPA在神经内分泌肿瘤中有价值;FAPI在胃癌评估中崭露头角。

关键数值与推荐

  • 文献检索获得449篇科学文章,筛选后选择173项Meta分析评估证据强度,最终考虑64项Meta分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 按检索和选择标准,未筛选到满意的Meta分析用于食管癌诊断/检测、小细胞肺癌和肝细胞癌诊断/检测及N分期、黑色素瘤和默克尔细胞癌诊断/检测及M分期、宫颈癌、外阴癌和阴茎癌诊断/检测及M分期、肺和胃肠胰神经内分泌肿瘤N和M分期、睾丸癌和软骨肉瘤N和M分期、分化型甲状腺癌、膀胱癌和肛管癌M分期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: For several years, oncological positron emission tomography (PET) has developed beyond 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG). This umbrella review of meta-analyses aims to provide up-to-date, comprehensive, high-level evidence to support appropriate referral for a specific radiopharmaceutical PET/computed tomography (CT) or PET/magnetic resonance (MR) in the diagnosis and staging of solid cancers other than brain malignancies. METHODS: We performed a systematic literature search on the PubMed/MEDLINE and EMBASE databases for meta-analyses assessing the accuracy of PET/CT and/or PET/MRI with [18F]FDG, somatostatin- receptor-targeting 68Ga-DOTA-peptides, 18F-labelled dihydroxyphenylalanine ([18F]DOPA), prostate-specific membrane antigen (PSMA)-targeted radioligands, and fibroblast activation protein inhibitors (FAPI) in the diagnosis/disease characterisation and staging of solid cancers other than brain tumours. RESULTS: The literature search yielded 449 scientific articles. After screening titles and abstracts and applying inclusion and exclusion criteria, we selected 173 meta-analyses to assess the strength of evidence. One article was selected from references. Sixty-four meta-analyses were finally considered. The current evidence corroborates the role of [18F]FDG as the main player in molecular imaging; PSMA tracers are useful in staging and re-staging prostate cancer; somatostatin-targeting peptides (e.g. [68Ga]Ga- DOTA-TOC and -TATE) or [18F]DOPA are valuable in neuroendocrine tumours (NETs). FAPI has emerged in gastric cancer assessment. According to search and selection criteria, no satisfactory meta-analysis was selected for the diagnosis/detection of oesophageal cancer, the diagnosis/detection and N staging of small cell lung cancer and hepatic cell carcinoma, the diagnosis/detection and M staging of melanoma and Merkel cell carcinoma, cervical, vulvar and penis cancers, the N and M staging of lung and gastroenteropancreatic NET, testicular cancer, and chondrosarcoma, and the M staging of differentiated thyroid, bladder and anal cancers. CONCLUSION: The comprehensive high-level evidence synthesised in the present umbrella review serves as a guiding compass for clinicians and imagers, aiding them in navigating the increasingly intricate seascape of PET examinations.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kirienko M, Gelardi F, Fiz F, et al. Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication. Eur J Nucl Med Mol Imaging. 2024. PMID: 39256216. doi:10.1007/s00259-024-06882-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。